• About Nektar
  • Our Leadership
  • Corporate Giving
  • Locations
  • Contacts
• Pipeline
  • Pipeline Overview
  • Nektar Proprietary Products
  • Nektar Partnered Products
  • Drug Development Platforms
• Partners
  • Nektar Partners
• Investor Relations
  • Press Releases
  • Stock Information
  • Financial Events Calendar
  • Analyst Coverage
  • Annual and Financial Reports
  • Corporate Governance
  • Investor Contacts
  • FAQ
  • Investor Advisory
• Media Room
  • Lead Product Backgrounder
  • Press Releases
  • Press Kit
  • Media Contacts
• Information Center
  • Scientific & Partnering Events
  • Multimedia
  • Library
  • Email Alerts
• Careers
  • Life at Nektar
  • Career Opportunities
  • Recruitment Calendar
  • Summer Internships
  • Benefits
  • Recruiting Information
  • Nektar Employee Foundation

• Pipeline Overview
• Nektar Proprietary Products
• Nektar Partnered Products
• Drug Development Platforms
  • Advanced PEGylation Technology
  • Advanced Pulmonary Delivery

Many biopharmaceuticals suffer from performance problems due to short half lives, immunogenicity, and poor solubility and stability. Clinically proven Nektar Advanced PEGylation Technology can improve performance and dosing convenience of peptides, proteins, antibodies, oligonucleotides and many small molecules by optimizing pharmacokinetics, increasing bioavailability, and decreasing immunogenicity and dosing frequency. Nektar Advanced PEGylation Technology also can increase therapeutic efficacy by enabling increased drug concentration, improved biodistribution, and longer dwell time at the site of action. As a result, therapeutic drug concentrations can be achieved with less frequent dosing—a significant benefit to patients who are taking injected drugs.

Nektar Advanced PEGylation Technology has been essential in the creation of several approved and marketed products including:

• Neulasta® for the treatment of neutropenia
• Macugen® for the treatment of exudative (wet) age-related macular degeneration
• PEGASYS® for the treatment of hepatitis C
• Somavert® for the treatment of acromegaly
• DuraSeal® Dural Sealant System for sealing sutured dura mater incisions following brain surgery

When attached to a drug, polyethylene glycol (PEG) polymer chains can sustain bioavailability by protecting the drug molecules from immune responses and other clearance mechanisms. In an aqueous medium, the long, chain-like PEG molecule is heavily hydrated and in rapid motion. This motion causes the PEG to sweep out a large volume and prevent the interference of other molecules.

> View the PEGylation animation